Association of BRCA, homologous recombination deficiency (HRD), and PD-L1 with clinical outcomes in patients receiving atezolizumab vs placebo combined wtih chemotherapy + bevacizumab for newly diagnosed ovarian cancer: Exploratory analyses from IMagyn050/GOG 3015/ENGOT-OV39
IMagyn050 is a randomized phase 3 trial evaluating the addition of atezolizumab to carboplatin/paclitaxel/bevacizumab in newly diagnosed ovarian cancer. In the present exploratory analysis, outcomes in this trial were analyzed according to BRCA1/2, homologous recombination deficiency, and PD-L1 status.